{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    14,
    17,
    37,
    41,
    47,
    52
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Diet and Exercise Counseling",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.9.3",
        "sectionTitle": "Diet and Exercise Counseling",
        "description": "Reference for subjects to adhere to diet and exercise counseling"
      },
      {
        "id": "ref_2",
        "name": "Study Flow Chart",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Flow Chart/Time and Event Schedule",
        "description": "Reference to the study flow chart and time/event schedule"
      },
      {
        "id": "ref_3",
        "name": "Birth Control Methods",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.4",
        "sectionTitle": "Women of Childbearing Potential",
        "description": "Reference regarding pregnancy and birth control methods"
      },
      {
        "id": "ref_4",
        "name": "Hypoglycemia Episodes",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.5.1",
        "sectionTitle": "Discontinuation Guidelines due to Protocol-Defined Hypoglycemia",
        "description": "Reference for protocol-defined hypoglycemia episodes leading to discontinuation"
      },
      {
        "id": "ref_5",
        "name": "CGM Requirements",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.9.4.3",
        "sectionTitle": "Continuous Glucose Monitoring",
        "description": "Reference for CGM completion requirements and optional phone visits"
      },
      {
        "id": "ref_6",
        "name": "Table 4-1 Footnote Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4",
        "sectionTitle": "Study Drug",
        "description": "Reference to packaging details in Table 4-1 footnotes"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Subjects are not allowed to change their insulin administration methods (MDI or CSII) throughout the study. Under certain situations (eg, the replacement of an insulin pump), the subjects who are on CSII may be on temporary use of MDI. They should restart CSII administration as early as feasible. The period of time when a subject is on temporary use of MDI should not be more than 2 weeks",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "3.5 Discontinuation of Subjects from Treatment",
        "pageNumber": 38
      },
      {
        "id": "annot_2",
        "text": "Blinded dapagliflozin 10 mg kit contains 2 bottles of dapagliflozin 5 mg film-coated tablets (35 count). Blinded dapagliflozin 5 mg kit contains 1 bottle of dapagliflozin 5 mg film-coated tablets (35 count) and 1 bottle of placebo for dapagliflozin film-coated tablets (35 count)",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 4-1",
        "pageNumber": 42
      },
      {
        "id": "annot_3",
        "text": "Blinded placebo kit contains 2 bottles of placebo for dapagliflozin film-coated tablets (35 count)",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 4-1",
        "pageNumber": 42
      },
      {
        "id": "annot_4",
        "text": "If a lead-in subject fails lead-in prior to the Day 1 visit, the CGM will not be required to be completed between the week-2 visit and the Day 1 visit",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5.1-1",
        "pageNumber": 48
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "02",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-05-18",
        "description": "Revised Protocol 02 incorporating Amendment 05. Primary purpose to provide study visit scheduling flexibility and update DKA assessments.",
        "amendmentNumber": "05"
      },
      {
        "id": "ver_2",
        "versionNumber": "01",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-05-06",
        "description": "Revised Protocol 01 incorporating Amendment 03. Modified Inclusion/Exclusion Criteria based on EMA feedback.",
        "amendmentNumber": "03"
      },
      {
        "id": "ver_3",
        "versionNumber": "Original",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-02-05",
        "description": "Original Protocol",
        "amendmentNumber": "N/A"
      }
    ],
    "summary": {
      "referenceCount": 6,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}